Evolent Health, Inc. (NYSE:EVH) Holdings Decreased by American Century Companies Inc.

American Century Companies Inc. trimmed its holdings in Evolent Health, Inc. (NYSE:EVH - Free Report) by 91.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,031 shares of the technology company's stock after selling 1,266,153 shares during the quarter. American Century Companies Inc. owned about 0.10% of Evolent Health worth $1,283,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in EVH. Boston Partners raised its holdings in shares of Evolent Health by 92.0% during the 4th quarter. Boston Partners now owns 2,444,006 shares of the technology company's stock worth $27,097,000 after acquiring an additional 1,171,304 shares during the period. Harbor Capital Advisors Inc. increased its stake in Evolent Health by 90.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company's stock worth $9,036,000 after purchasing an additional 380,790 shares during the period. Brighton Jones LLC acquired a new position in shares of Evolent Health in the fourth quarter worth $3,927,000. Royce & Associates LP boosted its holdings in Evolent Health by 130.5% in the fourth quarter. Royce & Associates LP now owns 576,200 shares of the technology company's stock valued at $6,482,000 after purchasing an additional 326,200 shares during the period. Finally, Franklin Resources Inc. grew its stake in Evolent Health by 40.8% during the 3rd quarter. Franklin Resources Inc. now owns 909,776 shares of the technology company's stock worth $24,682,000 after purchasing an additional 263,815 shares in the last quarter.

Insider Activity at Evolent Health

In other news, Director Brendan B. Springstubb acquired 5,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of $8.75 per share, for a total transaction of $43,750.00. Following the acquisition, the director now directly owns 11,842 shares in the company, valued at $103,617.50. This trade represents a 73.08 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Diane Holder purchased 2,735 shares of Evolent Health stock in a transaction on Thursday, March 6th. The shares were acquired at an average cost of $9.33 per share, for a total transaction of $25,517.55. Following the completion of the transaction, the director now owns 70,584 shares of the company's stock, valued at $658,548.72. This represents a 4.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 74,000 shares of company stock worth $666,315. 1.60% of the stock is currently owned by insiders.

Evolent Health Price Performance

EVH traded up $0.36 during midday trading on Wednesday, reaching $9.65. 51,194 shares of the company's stock were exchanged, compared to its average volume of 2,509,478. The business's 50-day moving average price is $9.69 and its 200 day moving average price is $13.58. The stock has a market capitalization of $1.12 billion, a PE ratio of -11.75 and a beta of 1.20. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health, Inc. has a 1-year low of $8.35 and a 1-year high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). The firm had revenue of $646.54 million during the quarter, compared to analysts' expectations of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. As a group, equities analysts anticipate that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EVH. JMP Securities restated a "market outperform" rating and set a $12.00 target price on shares of Evolent Health in a research note on Friday, February 14th. Needham & Company LLC reiterated a "buy" rating and set a $15.00 target price on shares of Evolent Health in a research note on Friday, February 21st. Truist Financial lowered their price objective on Evolent Health from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. JPMorgan Chase & Co. lowered their price target on Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a report on Monday, March 10th. Finally, Canaccord Genuity Group reduced their price objective on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $17.64.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.